Czech and Slovak Ophthalmology 52 Original article Active Clinical Trials Testing New Therapies for Stargardt Disease Kousal Bohdan Ďuďáková Ľubica https://orcid.org/0000-0003-4718-8955 Hlavatá Lucie 30 1 2016 1 5

Purpose: To provide information on currently ongoing clinical trials for Stargardt disease. Methods: We have searched the clinical trial register (www.clinicaltrials.gov) for the keyword „Stargardt“ and list active ongoing studies. Results: There are currently eight registered clinical trials enrolling patients with Stargardt disease; all in phase I or II aiming at four mechanisms of action: inhibition of the production of vitamin A toxic dimers, gene therapy restoring wild type transcription of the ABCA4 gene, neuroprotection preventing retinal cells from oxidative damage, and replacement of the damaged retinal pigment epithelium using stem cell therapy. The basic prerequisite for enrolment in the vast majority of clinical trials is confirmation of the clinical diagnosis by mutational analysis. Conclusion: The wide variety of therapies that are registered as clinical trials for Stargardt disease significantly raises the possibility that effective treatments will be available in thenear future for this currently incurable condition and that molecular genetic testing should be increasingly considered.

 Stargardt disease clinical trial ABCA4 mutation References Adler L 4th, Boyer NP, Chen C, et al.: The 11-cis retinal origins of lipofuscin in the retina. Prog Mol Biol Transl Sci, 134; 2015: e1–12. Al-Saikhan, FI.: The gene therapy re - volution in ophthalmology. Saudi J Ophthalmol, 27; 2013: 107-11. Bainbridge, JWB., Mehat, MS., Sundaram, V., et al.: Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med, 372; 2015: 1887–97. Binley K, Widdowson P, Loader J, et al.: Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Invest Ophthalmol Vis Sci, 54; 2013: 4061–71. Bisti, S., Maccarone, R., Falsini B.: Saffron and retina: neuroprotection and pharmacokinetics. Vis Neurosci, 31; 2014: 355-61. Charbel Issa, P., Barnard, AR., Herrmann, P., et al.: Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. Proc Natl Acad Sci U S A, 112; 2015: 8415–20. Falsini, B., Piccardi, M., Minnella, A., et al.: Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Invest Ophthalmol Vis Sci, 51; 2010: 6118–24. Han, Z., , Conley, SM., Makkia, RS., et al.: DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest, 122; 2012: 3221–6. Han, Z., Conley, SM., Naash, MI.: Gene therapy for Stargardt disease associated with ABCA4 gene. Adv Exp Med Biol, 801; 2014: 719–24. degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet, 385; 2015: 509–16. Kao, LS., Tyson, JE., Blakely ML., et al.: Clinical research methodology I: introduction to randomized trials. J Am Coll Surg, 206; 2008: 361–9. Kong, J., Kim, SR., Binley, K., et al.: Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther, 15; 2008: 1311–20. Kousal, B., et al.: Molekulárně genetická příčina a klinický nález u dvou probandů se Stargardtovou chorobou. Čes a slov Oftal, 70; 2014: 228–33. Lois, N., Holder, GE., Bunce, C., et al.: Phenotypic subtypes of Stargardt macular dystrophy-fundus flavimaculatus. Arch Ophthalmol, 119; 2001: 359–69. Mihai, DM., Washington, I.: Vitamin A dimers trigger the protracted death of retinal pigment epithelium cells. Cell Death Dis, 5; 2014: e1348. Purushothuman, S., Nandasena, C., Peoples, CL., et al.: Saffron pre-treatment offers neuroprotection to Nigral and retinal dopaminergic cells of MPTP -Treated mice. J Parkinsons Dis, 3; 2013: 77–83. Rivera, A., White, K., Stöhr. H., et al.: A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration. Am J Hum Genet, 67; 2000: 800–13. Schwartz, SD., Hubschman, JP., Heilwell, G., et al.: Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet, 379; 2012: 713–20. Schwartz, SD., Regillo, CD., Lam, BL., et al.: Human embryonic stem cellderived retinal pigment epithelium in patients with age-related macular Vasireddy, V., Wong, P., Ayyagari, R.: Genetics and molecular pathology of Stargardt-like macular degeneration. Prog Retin Eye Res, 2010; 29: 191–207. Weiss JN, Levy S, Malkin A.: Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a preliminary report. Neural Regen Res, 10; 2015: 982–8. Weiss JN, Levy S, Benes SC.: Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy. Neural Regen Res, 10; 2015: 1507–15. Weng, J., Mata, NL., Azarian, SM., et al.: Insights into the function of Rim protein in photoreceptors and etiology of Stargardt’s disease from the phenotype in abcr knockout mice. Cell, 98; 1999: 13–23. Yang, Z., Chen, Y., Lillo, C., et al.: Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. J Clin Invest, 2008; 118: 2908–16. Zahabi, A., Shahbazi, E., Ahmadieh, H., et al.: A new efficient protocol for directed differentiation of retinal pigmented epithelial cells from normal and retinal disease induced pluripotent stem cells. Stem Cells Dev, 21; 2012: 2262–72. Zernant, J., Schubert, C., Im, KM., et al.: Analysis of the ABCA4 gene by nextgeneration sequencing. Invest Ophthalmol Vis Sci, 52; 2011: 8479–87.